Airway mucosal host defense is key to genomic regulation of cystic fibrosis lung disease severity Authors: Polineni D, Dang H, Gallins PJ, et al. Am J Respir Crit Care Med 2017; in press [https://doi.org/10.1164/rccm.201701-0134OC]. Severity of lung disease can vary widely amongst people with cystic fibrosis (CF), even within populations possessing the same genotype. Addressing the key disease modifying factors has the potential to offer much better outcomes for individuals undergoing more rapid disease progression. Studies to identify these factors have, to date, performed genome-wide association studies (GWAS) and interpreted gene signatures against cohort clinical data or functional data obtained from immune cell lines.
To improve upon these studies, a new collaborative effort by Polineni et al. performed RNA sequencing on 134 primary nasal epithelial tissue biopsies and married the transcriptomic data to both lung disease severity and GWAS signatures. They hypothesised that this approach would reveal novel gene networks driving extent of disease severity.
A key finding was that the 18 top ranked genes common to both the transcriptomic activity in nasal epithelia and GWAS pathways were nearly all associated with airway mucosal host-defence. The top five genes for a severe CF lung phenotype were EDN1, TLR2, HLA-DRB1, IL8 and EDN2. Importantly, these 18 genes and their biological pathways all relate to processes understood to be defective in CF -innate immunity, antiviral hostdefence and apoptosis. Furthermore, transcriptomic data highlighted pathways that have been shown elsewhere to correlate with CF disease severity, for example the methionine salvage pathway.
Because nasal sampling is well tolerated, there is potential to apply this methodology to cohorts of other respiratory diseases such as asthma or chronic obstructive pulmonary disease, which often display significant variability in phenotypes and progression. The "omics" era heralds significant promise for tackling complex respiratory diseases. Reviewed by: Luke Garratt (Australia, Assembly 7)
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